Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib1
AstraZeneca today announced that the European Commission (EC) has approved a new indication for Faslodex (fulvestrant) in combination with a CDK4/6 inhibitor, palbociclib, for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.1
David Fredrickson, Executive Vice President, Head of the Oncology Business Unit at AstraZeneca, said: “For many years fulvestrant has been used as an effective monotherapy treatment for women with hormone receptor positive breast cancer. The first EU approval of fulvestrant for use in combination with a CDK4/6 inhibitor reinforces the value of fulvestrant as an endocrine agent of choice for advanced breast cancer patients, building on the EU first-line monotherapy approval earlier this year with FALCON.”
The EU approval is based on data from the Phase III PALOMA-3 trial, which showed a statistically significant increase in investigator-assessed median PFS of 4.9 months (9.5 months vs 4.6 months) in patients who received fulvestrant 500 mg and palbociclib 125 mg over fulvestrant and placebo (HR: 0·46; 95% CI: 0·36–0·59; p<0·0001).2
– ENDS –
NOTES TO EDITORS
About Advanced Breast Cancer
Advanced/metastatic breast cancer refers to Stage III and IV breast cancer. Stage III disease may also be referred to as locally-advanced breast cancer, while metastatic disease is the most-advanced stage of breast cancer (Stage IV), and occurs when cancer cells have spread beyond the initial tumour site to other organs of the body outside the breast. Since there is no cure for the disease, the goal of current treatment is to delay disease worsening or death. In 2012, there were an estimated 1.67 million new cases worldwide – one in four of all cancer cases. In Europe the estimated 5-year prevalence of breast cancer in 2012 was 1,814,572 cases.
PALOMA-3 is a Phase III international, randomised, double-blind, parallel group, multicentre study, sponsored by Pfizer Inc., of fulvestrant plus palbociclib vs fulvestrant plus placebo conducted in women with HR+/HER2- advanced or metastatic breast cancer, regardless of their menopausal status, whose disease progressed after endocrine therapy. The study evaluated 521 pre/postmenopausal women who were randomised 2:1 to fulvestrant plus
palbociclib or fulvestrant plus placebo. Women who were either premenopausal (meaning they had not reached menopause), or perimenopausal (meaning that their bodies were making the natural transition toward menopause), were therapeutically induced to become postmenopausal and represented 20.7% of the study population.
Patients enrolled in this study had a median age of 57 years (range 29 to 88). The majority of patients in the study were white (74%). All patients had an ECOG (Eastern Cooperative Oncology Group) PS of 0 or 1, and 80% were postmenopausal. All patients had received prior systemic therapy and 75% of patients had received a previous chemotherapy regimen. Twenty-five percent of patients had received no prior therapy in the metastatic disease setting, 60% had visceral metastases, and 22% had bone only disease.
Fulvestrant 500 mg was given as two 5 ml injections, one in each buttock, on days 1, 15, 29 and once monthly (28 ± 3 days) thereafter. Palbociclib was given orally at a dose of 125 mg daily for 21 consecutive days followed by 7 days off treatment. Patients continued to receive their assigned treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.
Fulvestrant is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on anti-oestrogen therapy.
In the US, fulvestrant is licensed for use with palbociclib for the treatment of women with HR+, HER2- locally advanced or metastatic breast cancer, whose cancer has progressed after endocrine therapy. In Japan, fulvestrant is also approved for use in combination with any CDK4/6 inhibitor. Fulvestrant represents a hormonal treatment approach that helps to slow tumour growth by blocking and degrading the oestrogen receptor – a key driver of disease progression.
Fulvestrant is approved in over 80 countries as a monotherapy to treat ER+ advanced breast cancer patients. It is currently being evaluated in combination with medicines from various drug classes for the treatment of women with HR+ advanced breast cancer.
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s five Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody-Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
1 European Commission. Pharmaceuticals - Community Register.
Available from: http://ec.europa.eu/health/documents/community-register/html/h269.htm
[Last Accessed November 2017]
2 Cristofanilli M, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, Phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-39
+44 (0)7818 524012
+1 301 398 3041
+44 (0)7384 239333
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Porta Solutions Has Been Awarded as Excellence of the Year Innovation & Leadership for the Flexible Production at Le Fonti Awards 201721.11.2017 20:04 | Tiedote
Maurizio Porta, Porta Solutions’CEO triumphed at the 32th edition of the IAIR Awards. The Award Ceremony, held at the at London Stock Exchange on the 20th of October 2017, crowned him the Excellence of the Year, Innovation & Leadership, for the Flexible Production. For being an Italian excellence since 1958, innovative leader in the sector of productive flexibility in the manufacturing world. In particular to be able to aim continually and strategically on innovation and customization to ensure the best performance and highest quality. “Flexible Production: produce what you sell, no stock, no stress, more cash" says Maurizio Porta. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005803/en/ Porta Solutions was awarded at the Le Fonti Awards (Photo: Business Wire) Today, the
China Global Investment Forum Hangzhou 2017 Opens21.11.2017 19:04 | Tiedote
On November 20, China Global Investment Forum Hangzhou 2017 opened. The forum was hosted by the Hangzhou Municipal People's Government and the Department of Commerce of Zhejiang Province, and organized by the Hangzhou Investment Promotion Bureau and Euromoney Institutional Investor PLC. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005723/en/ China Global Investment Forum Hangzhou 2017 Themed "Sharing the Opportunity of Hangzhou, Co-building a World-renowned City", the event brought together nearly 1,000 renowned experts, scholars and entrepreneurs from home and abroad, to interpret Hangzhou's economy, explore Hangzhou's future industries, look into the investment trends of the world and Hangzhou, and offer advice on improving Hangzhou's level of opening to the outside world, promoting
TechnipFMC, Saipem & Bureau Veritas Sign Partnership with Expert Teleportation21.11.2017 18:27 | Tiedote
BUREAU VERITAS, SAIPEM and TECHNIPFMC are teaming up to bring expert tele assistance to on-site operators within the specific context of the Oil & Gas sector (offshore, remote location, ATEX, IECEx, etc.) and have formed a collaborative partnership with EXPERT TELEPORTATION who will lead the project development. The 15-month long project will deliver a hands’ free device (modified smart glasses) adapted to use with personnel protective equipment. The adapted tool will connect an operator located on site anywhere in the world with a remote expert / analyst in real time via audio and video stream. This EXPERT TELEPORTATION project will enable higher operational efficiency, smarter and faster response time, improved safety and a reduced carbon footprint. ABOUT: In an increasingly competit
Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) from EMA in Newly Diagnosed Multiple Myeloma21.11.2017 17:40 | Tiedote
Janssen-Cilag International NV today announced the submission of a Type II variation application to the European Medicines Agency (EMA), for the immunotherapy DARZALEX®▼ (daratumumab). The application seeks to broaden the existing marketing authorisation to include daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. “This submission to health authorities takes us one step closer to our goal of redefining combination therapy in multiple myeloma, with the potential to make daratumumab available to more patients throughout the treatment continuum: from newly diagnosed, to heavily pre-treated,” said Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen Europe, Middle East and Africa (EMEA). “We look forward to working closely with the
Andersen Global Announces Expansion in Uganda21.11.2017 17:30 | Tiedote
Andersen Global is proud to announce a presence in Uganda by way of a Collaboration Agreement with Ligomarc Advocates, a financial and corporate tax and legal firm. The firm is led by Managing Partner, Kabiito Karamagi. The addition of Ligomarc Advocates as a Collaborating Firm of Andersen Global continues the organization’s expansion in Africa. Ligomarc is Andersen Global’s fourth location in Africa. “Integrity, excellence, and putting the client at the center have always been of paramount importance to us, and our collaboration with Andersen Global will allow us to ensure our clients receive the best-in-class service internationally,” commented Kabiito Karamagi. “The team at Andersen shares our values of outstanding, seamless client service and independence—this is a natural fit.” Ligomarc Advocates was founded as a sole practice over fifteen years ago by Ruth Sebatindira,
Keio Plaza Hotel Tokyo Hosts "Sky Jazz Night" Events in the "Premier Grand" Club Lounge21.11.2017 17:00 | Tiedote
Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host special jazz events for guests staying in our “Premier Grand” Club Floor on December 7, 8, 14, 15, and 16, 2017. A duo consisting of piano and contrabass artists will perform 30 minutes jazz sessions in our Club Lounge located on the 45th floor at 5:30p.m., 6:30p.m., and 7:30p.m. Guests listening to these jazz sessions can enjoy complimentary hors d’ oeuvres, and alcoholic and non-alcoholic beverages. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005017/en/ Club Floor "Premier Grand," Club Lounge (Photo: Business Wire) Our “Premier Grand” Club Floors were renovated and newly opened in December 2016, with guest rooms being fitted with various premium items
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme